Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes

Inclusion Criteria:

- Type 1 diabetes for 12 months or longer, hereof the last 3 months with injection
based therapies

- Current treatment with any basal insulin (e.g. insulin glargine, insulin detemir, NPH
insulin) using one or two daily injections and with three or more daily meal-time
insulin injections (e.g. insulin aspart, insulin lispro, insulin glulisine, human
insulin) used as bolus insulin therapy

- HbA1c maximum 10.0 % by central laboratory analysis

- Body Mass Index (BMI) below or equal to 35.0 kg/m^2

- Ability to self-manage insulin therapy as assessed by confirmation (verbal
confirmation at screening visit) of a changed insulin dose in the preceding two
months prior to screening

- Ability and willingness to adhere to the protocol including performance of self
measured plasma glucose (SMPG) profiles and self adjustment of insulin doses

Exclusion Criteria:

- Use within the last 3 months prior to Visit 1 of any antidiabetic glucose lowering
drug other than insulin

- Cardiovascular disease, within the last 6 months prior to visit 1, defined as:
stroke; decompensated heart failure New York Heart Association (NYHA) class III or
IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass
graft or angioplasty

- Uncontrolled treated/ untreated severe hypertension (systolic blood pressure above or
equal to 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure above or
equal to 100 mmHg)

- Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate
contraceptive measures according to local requirements

- Cancer and medical history of cancer (except basal cell skin cancer or squamous cell
skin cancer)